Leading a transformation in cancer care, where each patient’s treatment is informed by a deep understanding of the molecular changes that contribute to their disease

Foundation Medicine (NASDAQ:FMI) is a molecular information company dedicated to a transformation in cancer care in which treatment is informed by a deep understanding of the genomic changes that contribute to each patient's unique cancer. The company offers a full suite of comprehensive genomic profiling assays to identify the molecular alterations in a patient's cancer and match them with relevant targeted therapies, immunotherapies and clinical trials. Foundation Medicine's molecular information platform aims to improve day-to-day care for patients by serving the needs of clinicians, academic researchers and drug developers to help advance the science of molecular medicine in cancer.

Year Invested: 2010
Location: Cambridge, Mass.
Visit: www.foundationmedicine.com

Recent News

March 16, 2018
Foundation Medicine Advances Patient Access to Precision Medicine; Pursues Regulatory Approval for FoundationOne CDx™ in Japan

March 13, 2018
Foundation Medicine and Guardant Health Agree to Resolve False Advertising Lawsuit

March 8, 2018
Foundation Medicine to Present at Cowen and Company's 38th Annual Healthcare Conference

Read More News

Associated Team Members

Sarah Larson
Partner/Chief Human Resources Officer

Mark Levin

Neil Exter

Alexis Borisy